Top Markets
#1 0G 0G +24.46%
#2 SAFEcoin SAFEcoin +21.99%
#3 Zora Zora +20.33%
#4 Axelar Axelar +19.88%
#5 Full Moon Full Moon +18.98%
#6 AI XOVIA AI XOVIA +17.52%
#7 Merlin's Seal BTC Merlin's Seal BTC +16.60%
#8 Cysic Cysic +16.30%
#9 VVS Finance VVS Finance +15.88%
#10 Apertum Apertum +13.84%
Coin of the day
0G 0G
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Graphite Bio, Inc. Graphite Bio, Inc.

Graphite Bio, Inc.

GRPH
Rang in aandelen #12750
Graphite Bio, Inc. is a clinical-stage gene editing company dedicated to... Graphite Bio, Inc. is a clinical-stage gene editing company dedicated to developing innovative therapeutic solutions for severe and life-threatening illnesses across the United States. Its primary investigational therapy, GPH101, is an autologous, gene-edited hematopoietic stem cell product specifically engineered to directly correct the underlying mutation causing sickle cell disease, thereby restoring normal adult hemoglobin production. The company's pipeline also features GPH201, intended for the treatment of X-linked severe combined immunodeficiency syndrome, and GPH301, an experimental candidate designed to address Gaucher disease, a genetic disorder characterized by a deficiency in the glucocerebrosidase enzyme. Initially established as Integral Medicines, Inc., the company rebranded to Graphite Bio, Inc. in August 2020. Founded in 2017, Graphite Bio's operations are based out of its headquarters in South San Francisco, California.
Aandeelprijs
$22.26
Laatst gesynchroniseerd: 2024-03-22
Marktkapitalisatie
$553.40M
Verandering (1 dag)
0.00%
Verandering (1 jaar)
0.00%
Land
US
Handel Graphite Bio, Inc. (GRPH)

Categorie

Healthcare
Winst voor Graphite Bio, Inc. (GRPH)
Winst in 2026 TTM: 0
Volgens de meest recente financiële verslagen van Graphite Bio, Inc. bedraagt de huidige winst van het bedrijf 0. In 2026 behaalde het bedrijf een winst van 0, gelijk aan de winst van 2026, die 0 bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Graphite Bio, Inc. van 2026 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Winst van vergelijkbare bedrijven of concurrenten
Bedrijf Winst Winstverschil Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH